DUBLIN – Staten Biotechnology BV could earn as much as €430 million (US$488.1 million) in up-front, R&D and milestone payments from an option and acquisition agreement with Novo Nordisk A/S involving STT-5058, its preclinical antibody-based inhibitor of apolipoprotein C III (apoC-III), which regulates blood triglyceride levels.